Catalyst Wire Dossier Catalyst Wire Dossier

Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)

· CanSino Biologics Inc.
Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector), covering 2020-07-02 to 2024-04-23. Get the full timeline:

Most recent: Clinical Trial Update: Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19 [Phase 3]

See pricing